Beijing Pharmaceutical and Medical Device Innovation Service Station (Haidian) Officially Launched
On September 25, the unveiling ceremony for the Beijing Drug and Medical Device Innovation Service Station (Haidian) was successfully held in Haidian District, marking the official establishment of the service station on Zhongguancun Entrepreneurship Street in Haidian District. Zhang Ge, Secretary of the Haidian District Committee of the Communist Party of China, and Sun Liguang, Member of the Party Leadership Group of the Beijing Municipal Administration for Market Regulation and Secretary of the Party Leadership Group of the Beijing Medical Products Administration, jointly unveiled the plaque for the Beijing Drug and Medical Device Innovation Service Station (Haidian). Cao Wei, Director of the Beijing Medical Products Administration; Wang Houting, Member of the Party Leadership Group and Deputy Director; and Yue Li, Member of the Standing Committee of the Haidian District Committee of the Communist Party of China and Executive Deputy District Mayor of Haidian District, attended the event. The ceremony was hosted by Lin Hang, Deputy District Mayor of Haidian District. A total of 100 attendees from universities and research institutes, medical institutions, industry enterprises, and media outlets gathered to witness the official launch of this new service platform for the pharmaceutical and health industries.
Establishment of Haidian StationThe pharmaceutical and healthcare industry service network, featuring a coordinated “North-South” layout, has been further refined, filling the gap in Haidian District’s municipal-level professional pharmaceutical innovation services and injecting new momentum into the development of the regional pharmaceutical and healthcare industry. Meanwhile, with “integrated innovation and AI empowerment” as its core features, this service station will precisely align with Haidian District’s industrial advantages—namely, its high concentration of universities, abundant scientific research resources, and vibrant corporate innovation—thereby establishing a professional and efficient service bridge to support the high-quality development of the city’s pharmaceutical and healthcare industry.
Construction and Operation of Haidian StationIn deep implementation of the requirements set forth in the “Several Measures of Beijing Municipality to Support the High-Quality Development of Innovative Pharmaceuticals (2025),” we focus on addressing the “pain points” and “bottlenecks” in the research, development, and commercialization of innovative drugs and medical devices. By providing full-chain services—including policy consultation, technical guidance, and regulatory approval liaison—we have successfully been selected as one of the units undertaking the “Open Competition Mechanism” pilot projects within the National Independent Innovation Demonstration Zone. From policy implementation to closed-loop service delivery, and from inclusion in the pilot program to prioritized advancement, every strategic step taken by the Haidian Station is closely aligned with industry needs and targeted at key developmental priorities. Moving forward, it will continue to serve as a crucial catalyst for the transformative breakthroughs of innovative drugs and medical devices, thereby sustaining the vibrant innovation momentum of Beijing’s pharmaceutical industry.
As one of the four core hubs for the pharmaceutical and health industries in Beijing, Haidian District is home to more than 700 pharmaceutical and healthcare companies, including 20 listed enterprises. It has gathered 33 national-level “Little Giant” firms specializing in specialized, refined, distinctive, and innovative fields, boasting abundant clinical and R&D resources. The district hosts 57 medical institutions at the secondary level or above, 36 national key laboratories, 14 clinical medicine research centers, and 15 hospital-based research institutes. Leveraging prestigious academic and research institutions such as Tsinghua University, Peking University, and the Chinese Academy of Sciences, as well as renowned medical facilities like Peking University Cancer Hospital, PLA General Hospital (301 Hospital), and Xiyuan Hospital, Haidian District demonstrates distinct advantages characterized by comprehensive basic disciplines, concentrated clinical resources, and a robust talent pipeline.
Service Positioning:
Full-Chain Integrated Platform, AI-Empowered Regulation
Yao Hongbo, General Manager of Beijing Zhongguancun Science City Innovation Development Co., Ltd.Promotion of the Haidian Station: As a full-chain comprehensive service platform, it aligns closely with the core regulatory review and approval functions of drug administration authorities. By integrating resources from multiple municipal and district departments and leveraging Haidian District’s advantages in scientific research, healthcare, and the AI industry, it provides precise support to pharmaceutical and health enterprises—from early-stage R&D to market commercialization—thereby accelerating product incubation. The station offers end-to-end services, including policy consultation, technical guidance, and regulatory liaison. Key initiatives include prioritized inspections and expedited reviews for key projects, establishing green channels for production licensing, organizing policy training programs, and promoting med-tech convergence and real-world evidence studies.
He Ting, Chairman of Beijing ImmuneOnco Biopharmaceuticals Co., Ltd.stated that the service station will address the challenges enterprises face in cross-regional coordination for regulatory review and approval, significantly enhance R&D efficiency, and provide support for the rapid market launch of products.
Ma Lizhen, Chairman of Guoke Ion Medical Technology Co., Ltd.He expressed strong agreement and high expectations for the pre-review service principle of “early intervention, tailored strategies for each product.” He believes this principle precisely aligns with the practical needs of enterprises at various stages of development, and sincerely hopes that service platforms will provide continuous and adaptive support during the start-up, growth, and upgrading phases of businesses.
Deepening Compliance
Strong Policies, Superior Training,Safeguarding the Pharmaceutical and Health Industries
At the event, Chen Liwei, Director of the Regulations Division of the Beijing Municipal Medical Products Administration, provided an interpretation of innovative drug regulatory policies for enterprises and announcedChina’s First Provincial-Level Compliance Guidelines for Biopharmaceutical Enterprises—“Beijing Compliance Guidelines for Biopharmaceutical Enterprises”, aiming to help biopharmaceutical companies rapidly identify high-risk “minefields” for compliance under the current regulatory and policy framework, guide enterprises in establishing effective compliance and risk management systems, and promote compliant business operations.
The event also invited legal experts in the field of drug regulation to deliver lectures on legal interpretation, risk identification, and the establishment of compliance systems, drawing on industry hotspots, challenges, and typical cases, thereby providing professional support for enterprises to enhance their compliance management capabilities.
The simultaneous release of this policy and the associated training initiative represents a significant measure by Haidian District to strengthen legal safeguards and support the innovative development of enterprises. Moving forward, the district will continue to prioritize enterprise needs to drive high-quality development in the regional pharmaceutical and health industry.
Future Outlook
Enhancing Service Networks, Leading Industry Innovation
A representative from the Beijing Municipal Medical Products Administration stated that, following the establishment of the Haidian Station, efforts will be continuously made to achieve comprehensive coverage of the drug regulatory service network. By focusing on core functions such as front-loading review and approval processes and prioritizing innovative products, the administration aims to facilitate the market approval of more original innovative products. The Municipal Medical Products Administration will also guide the platform to deepen its exploration of AI-assisted reviews and optimize “one-on-one” services, striving to ensure that by 2026, innovative medical devices across the city,AI Medical DevicesThe number of approvals continues to lead the country.
Establishment and Operation of Haidian Station
Flagship of the Haidian District Pharmaceutical and Health Industry Service System
Entering a New Phase
In the future, the platform will integrate resources from multiple municipal and district departments. Leveraging Haidian District’s strengths in scientific research, healthcare, and the artificial intelligence industry, and centered on the core features of “integrated innovation and AI empowerment,” it will provide enterprises with precise support spanning from early-stage R&D to market launch and commercialization, thereby injecting new momentum into the development of the regional pharmaceutical and health industry.
